{"id":798519,"date":"2025-01-07T09:12:28","date_gmt":"2025-01-07T14:12:28","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/shuttle-pharma-to-participate-in-the-lytham-partners-2025-investor-healthcare-summit-on-january-13-2025\/"},"modified":"2025-01-07T09:12:28","modified_gmt":"2025-01-07T14:12:28","slug":"shuttle-pharma-to-participate-in-the-lytham-partners-2025-investor-healthcare-summit-on-january-13-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/shuttle-pharma-to-participate-in-the-lytham-partners-2025-investor-healthcare-summit-on-january-13-2025\/","title":{"rendered":"Shuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025"},"content":{"rendered":"
\n

GAITHERSBURG, Md., Jan. 07, 2025 (GLOBE NEWSWIRE) — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (\u201cShuttle Pharma\u201d), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced that CEO, Anatoly Dritschilo, M.D., will participate in a webcasted fireside chat at the Lytham Partners 2025 Investor Healthcare Summit, taking place virtually on Monday, January 13, 2025.<\/p>\n

The fireside chat will take place at 3:30 p.m. Eastern time on Monday, January 13, 2025. The webcast can be accessed by visiting the conference home page at https:\/\/lythampartners.com\/health2025\/<\/a> or directly at https:\/\/lythampartners.com\/health2025\/shph<\/a>. A replay of the fireside chat will also be available through the same links.<\/p>\n

1×1 investor meetings will be available after the event upon request by contacting your Lytham representative at 1×1@lythampartners.com<\/a>.<\/p>\n

Dr. Dritschilo will discuss the Company\u2019s plans for 2025. Topics are expected to include the progress being made in its Phase 2 Clinical Trial of Ropidoxuridine for the treatment of patients with glioblastoma. The ongoing trial of the Company\u2019s lead candidate is currently enrolling patients at six nationally recognized cancer centers to treat patients with IDH wild-type, methylation negative glioblastoma, the target of the clinical trial. Further, Dr. Dritschilo is expected to discuss recent developments being made within its Shuttle Diagnostics subsidiary focused on its PC-RAD test for predicting outcomes following radiation therapy for localized prostate cancer, as well as its ligand to the prostate-specific membrane antigen (PSMA) as a potential diagnostic and therapeutic, or theranostic, molecule.<\/p>\n

\n
\n About Shuttle Pharmaceuticals<\/u>
\n <\/strong>\n <\/p>\n

Founded in 2012 by faculty members of the\u00a0Georgetown University\u00a0Medical Center, Shuttle Pharma is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT). Our mission is to improve the lives of cancer patients by developing therapies that are designed to maximize the effectiveness of RT while limiting the side effects of radiation in cancer treatment. Although RT is a proven modality for treating cancers, by developing radiation sensitizers, we aim to increase cancer cure rates, prolong patient survival and improve quality of life when used as a primary treatment or in combination with surgery, chemotherapy and immunotherapy. For more information, please visit our website at\u00a0www.shuttlepharma.com<\/u><\/a>.<\/p>\n

\n
\n Safe Harbor Statement<\/u>
\n <\/strong>\n <\/p>\n

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute \u201cforward-looking statements.\u201d These statements include, but are not limited to, statements concerning the development of our company. The words \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontinue,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201ctarget,\u201d \u201cwill,\u201d \u201cwould\u201d and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The reader is cautioned not to rely on such forward-looking statements. Such forward-looking statements relate to future events or our future performance. In evaluating these forward-looking statements, you should consider various factors, including our expectations regarding the success and\/or completion of our pre-clinical research; our success in completing any newly initiated clinical trials, commence new trials and obtain regulatory approval following such trials; challenges and uncertainties inherent in product research and development; and the uncertainty regarding future commercial success. These and other factors may cause our actual results to differ materially from any forward-looking statements. Forward-looking statements are only predictions and actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including factors discussed in the \u201cRisk Factors\u201d section of Shuttle Pharma\u2019s Annual Report on Form 10-K for the year ended December 31, 2023, as amended, filed with the SEC on September 4, 2024, as well other SEC filings. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, Shuttle Pharmaceuticals specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.<\/p>\n

\n Shuttle Pharmaceuticals<\/strong>
\n
Anatoly Dritschilo,\u00a0M.D., CEO
240-403-4212
info@shuttlepharma.com<\/u><\/a><\/p>\n

\n Investor Contacts<\/strong>
\n
Lytham Partners, LLC
Robert Blum
602-889-9700
shph@lythampartners.com<\/u><\/a>\u00a0<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

GAITHERSBURG, Md., Jan. 07, 2025 (GLOBE NEWSWIRE) — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (\u201cShuttle Pharma\u201d), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced that CEO, Anatoly Dritschilo, M.D., will participate in a webcasted fireside chat at the Lytham Partners 2025 Investor Healthcare Summit, taking place virtually on Monday, January 13, 2025. The fireside chat will take place at 3:30 p.m. Eastern time on Monday, January 13, 2025. The webcast can be accessed by visiting the conference home page at https:\/\/lythampartners.com\/health2025\/ or directly at https:\/\/lythampartners.com\/health2025\/shph. A replay of the fireside chat will also be available through the same links. 1×1 investor meetings will be available after … <\/p>\n

Continue reading “Shuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-798519","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nShuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shuttle-pharma-to-participate-in-the-lytham-partners-2025-investor-healthcare-summit-on-january-13-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"GAITHERSBURG, Md., Jan. 07, 2025 (GLOBE NEWSWIRE) — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (\u201cShuttle Pharma\u201d), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced that CEO, Anatoly Dritschilo, M.D., will participate in a webcasted fireside chat at the Lytham Partners 2025 Investor Healthcare Summit, taking place virtually on Monday, January 13, 2025. The fireside chat will take place at 3:30 p.m. Eastern time on Monday, January 13, 2025. The webcast can be accessed by visiting the conference home page at https:\/\/lythampartners.com\/health2025\/ or directly at https:\/\/lythampartners.com\/health2025\/shph. A replay of the fireside chat will also be available through the same links. 1×1 investor meetings will be available after … Continue reading "Shuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/shuttle-pharma-to-participate-in-the-lytham-partners-2025-investor-healthcare-summit-on-january-13-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-07T14:12:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNzMwMiM2NjgwNjYyIzIxODE2ODg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shuttle-pharma-to-participate-in-the-lytham-partners-2025-investor-healthcare-summit-on-january-13-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shuttle-pharma-to-participate-in-the-lytham-partners-2025-investor-healthcare-summit-on-january-13-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Shuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025\",\"datePublished\":\"2025-01-07T14:12:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shuttle-pharma-to-participate-in-the-lytham-partners-2025-investor-healthcare-summit-on-january-13-2025\\\/\"},\"wordCount\":693,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shuttle-pharma-to-participate-in-the-lytham-partners-2025-investor-healthcare-summit-on-january-13-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyNzMwMiM2NjgwNjYyIzIxODE2ODg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shuttle-pharma-to-participate-in-the-lytham-partners-2025-investor-healthcare-summit-on-january-13-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shuttle-pharma-to-participate-in-the-lytham-partners-2025-investor-healthcare-summit-on-january-13-2025\\\/\",\"name\":\"Shuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shuttle-pharma-to-participate-in-the-lytham-partners-2025-investor-healthcare-summit-on-january-13-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shuttle-pharma-to-participate-in-the-lytham-partners-2025-investor-healthcare-summit-on-january-13-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyNzMwMiM2NjgwNjYyIzIxODE2ODg=\",\"datePublished\":\"2025-01-07T14:12:28+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shuttle-pharma-to-participate-in-the-lytham-partners-2025-investor-healthcare-summit-on-january-13-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shuttle-pharma-to-participate-in-the-lytham-partners-2025-investor-healthcare-summit-on-january-13-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shuttle-pharma-to-participate-in-the-lytham-partners-2025-investor-healthcare-summit-on-january-13-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyNzMwMiM2NjgwNjYyIzIxODE2ODg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyNzMwMiM2NjgwNjYyIzIxODE2ODg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shuttle-pharma-to-participate-in-the-lytham-partners-2025-investor-healthcare-summit-on-january-13-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Shuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/shuttle-pharma-to-participate-in-the-lytham-partners-2025-investor-healthcare-summit-on-january-13-2025\/","og_locale":"en_US","og_type":"article","og_title":"Shuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 - Market Newsdesk","og_description":"GAITHERSBURG, Md., Jan. 07, 2025 (GLOBE NEWSWIRE) — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (\u201cShuttle Pharma\u201d), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced that CEO, Anatoly Dritschilo, M.D., will participate in a webcasted fireside chat at the Lytham Partners 2025 Investor Healthcare Summit, taking place virtually on Monday, January 13, 2025. The fireside chat will take place at 3:30 p.m. Eastern time on Monday, January 13, 2025. The webcast can be accessed by visiting the conference home page at https:\/\/lythampartners.com\/health2025\/ or directly at https:\/\/lythampartners.com\/health2025\/shph. A replay of the fireside chat will also be available through the same links. 1×1 investor meetings will be available after … Continue reading \"Shuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/shuttle-pharma-to-participate-in-the-lytham-partners-2025-investor-healthcare-summit-on-january-13-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-01-07T14:12:28+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNzMwMiM2NjgwNjYyIzIxODE2ODg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shuttle-pharma-to-participate-in-the-lytham-partners-2025-investor-healthcare-summit-on-january-13-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shuttle-pharma-to-participate-in-the-lytham-partners-2025-investor-healthcare-summit-on-january-13-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Shuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025","datePublished":"2025-01-07T14:12:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shuttle-pharma-to-participate-in-the-lytham-partners-2025-investor-healthcare-summit-on-january-13-2025\/"},"wordCount":693,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shuttle-pharma-to-participate-in-the-lytham-partners-2025-investor-healthcare-summit-on-january-13-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNzMwMiM2NjgwNjYyIzIxODE2ODg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shuttle-pharma-to-participate-in-the-lytham-partners-2025-investor-healthcare-summit-on-january-13-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/shuttle-pharma-to-participate-in-the-lytham-partners-2025-investor-healthcare-summit-on-january-13-2025\/","name":"Shuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shuttle-pharma-to-participate-in-the-lytham-partners-2025-investor-healthcare-summit-on-january-13-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shuttle-pharma-to-participate-in-the-lytham-partners-2025-investor-healthcare-summit-on-january-13-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNzMwMiM2NjgwNjYyIzIxODE2ODg=","datePublished":"2025-01-07T14:12:28+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shuttle-pharma-to-participate-in-the-lytham-partners-2025-investor-healthcare-summit-on-january-13-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/shuttle-pharma-to-participate-in-the-lytham-partners-2025-investor-healthcare-summit-on-january-13-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shuttle-pharma-to-participate-in-the-lytham-partners-2025-investor-healthcare-summit-on-january-13-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNzMwMiM2NjgwNjYyIzIxODE2ODg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyNzMwMiM2NjgwNjYyIzIxODE2ODg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shuttle-pharma-to-participate-in-the-lytham-partners-2025-investor-healthcare-summit-on-january-13-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Shuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/798519","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=798519"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/798519\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=798519"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=798519"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=798519"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}